Evgeni Gershman

Dr. Evgeni Gershman

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2018 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
EGEvgeni Gershman
Evgeni Gershman
ERElena Ridman
Elena Ridman
LFLudmila Fridel
Ludmila Fridel
OSOsnat Shtraichman
Osnat Shtraichman
BPBarak Pertzov
Barak Pertzov
MKMordechai Reuven Reuven Kramer
Mordechai Reuven Reuven Kramer

26 April 2022 in Thoracic Cancer
Verified
Journal Article
Open access
EGEvgeni Gershman
Evgeni Gershman
AIAlon Amram Ikan
Alon Amram Ikan
BPBarak Pertzov
Barak Pertzov
DRDror Rosengarten
Dror Rosengarten
MKMordechai Reuven Reuven Kramer
Mordechai Reuven Reuven Kramer
Background: The diagnostic yield of endobronchial ultrasound‐transbronchial needle aspiration (EBUS‐TBNA) from mediastinal lymph nodes ranges from 66%–89%. However, in many cases cytologic material is not sufficient for full molecular evaluation. A novel method of transcarinal cryobiopsy aims to provide bronchoscopically obtained, larger specimen samples from mediastinal lymph nodes. We aimed to assess the efficacy and safety of transcarinal EBUS‐guided lymph node cryobiopsy.Methods: Patients referred for EBUS‐TBNA, based on abnormal mediastinal clinical and radiographic findings, were enrolled into this prospective interventional study between July 2020 and August 2021. All EBUS‐TBNA procedures were performed using ProCore 22G needle (Cook Medical) to create, both a transcarinal tract for the cryoprobe and to obtain TBNA samples. For EBUS guided transcarinal cryobiopsy, we used flexible 1.1 mm or 1.7 mm cryoprobe inserted into the working channel of the EBUS scope and into the target subcarinal lymph node.Results: Twenty‐four patients with male predominance 2:1 and mean age of 60.12 ± 10.16 years were enrolled. All target lymph nodes had hypoechoic, homogenic consistency with demarcated borders, without central structures. Cryobiopsy provided pathological diagnosis in 20 cases (83.33%), with 1.1 mm cryoprobe in 14 and with 1.7 mm cryoprobe in 6 cases. In one case each, pathology was provided by TBNA or by cryoprobe alone. No immediate or late complications were encountered during the procedures.Conclusion: Transcarinal EBUS guided lymph node cryobiopsy following EBUS‐TBNA proved to be efficient with a high diagnostic yield and can be considered safe, because no immediate or late complications occurred.

10 October 2024 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
RGRegina Pikman Gavriely
Regina Pikman Gavriely
OFOphir Freund
Ophir Freund
BTBoaz Tiran
Boaz Tiran
TPTal Moshe Perluk
Tal Moshe Perluk
EKEyal Kleinhendler
Eyal Kleinhendler
EGEvgeni Gershman
Evgeni Gershman
Background: Advanced bronchoscopic procedures have become a widely prevalent evaluation and treatment modality. These procedures require appropriate sedation and respiratory support. This study directly compares three respiratory support methods during advanced bronchoscopy.Methods: This three-arm, prospective, block randomised trial included 60 consenting adult patients that were referred for advanced bronchoscopy involving endobronchial ultrasound (EBUS) with transbronchial needle aspiration and met inclusion/exclusion criteria. Patients were randomised to undergo bronchoscopy through a laryngeal mask airway (LMA) or with a high-flow nasal cannula (HFNC) or low-flow nasal cannula (NC), with bronchoscopy performed through a bite block. Demographic, procedural and clinical parameters were compared between the three groups, including complications, oxygenation, ventilation and need for intervention.Results: Analysis according to intention to treat was made for the 20 patients in each arm. There were no significant differences in demographic parameters, pre-morbidities and procedure type and duration between groups. Hypoxia was significantly more common in the NC group (90%) compared with the LMA (45%) and HFNC (26%) groups (p<0.01). The need for interventions and their number were also lower in the LMA (40%) and HFNC (52.6%) groups compared with the NC group (90%, p<0.01). A multivariate analysis confirmed both HFNC and LMA as independent predictors of a lower rate of recurrent desaturation events and fewer complications in general compared with NC.Conclusion: In this prospective randomised trial, we demonstrated the advantages of using LMA or HFNC over NC during advanced bronchoscopy with EBUS.

21 June 2020 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
EGEvgeni Gershman
Evgeni Gershman
AZAlona Zer
Alona Zer
BPBarak Pertzov
Barak Pertzov
OSOsnat Shtraichman
Osnat Shtraichman
DSDorit Shitenberg
Dorit Shitenberg
MKMordechai Kramer
Mordechai Kramer
Background Patients with idiopathic pulmonary fibrosis (IPF) have significantly higher incidence of lung cancer (LC) relative to the general population. There is a further increase in LC incidence in patients with IPF subsequent to lung transplant, specifically in patients with IPF undergoing single lung transplant. Objectives To examine the incidence and characteristics of LC in patients with IPF during follow-up and after lung transplantation (LTX). Methods We conducted a retrospective analysis of all patients with IPF diagnosed with LC in Rabin Medical Center, Israel, over an 11-year period. We compared the characteristics of transplanted patients with IPF diagnosed with LC to patients with IPF who did not undergo lung transplant. Data were accessed from database registries using the words ‘fibrosis’, ‘lung-cancer’ and ‘lung-transplantation’. Demographic parameters included age, gender and smoking history (pack years). Clinical-pathological parameters included lapse in time from IPF diagnosis to LC, type of malignancy, affected pulmonary lobe, and stage at diagnosis, oncological treatment and survival. Results Between 2008 and 2018, 205 patients with IPF underwent lung transplantation at our medical centre. Double LTX was performed in 83 and single LTX in 122 cases. Subsequently, 15 (12.3%) single LTX patients were diagnosed with LC during the study period. During the same period, of 497 non-transplanted patients with IPF followed in our centre, 45 (9.1%) were diagnosed with LC. In all 15 transplanted patients with IPF, LC was diagnosed exclusively in the native fibrotic lung. LC incidence was higher in the transplanted as compared with the non-transplanted group, but this difference did not reach statistical significance (OR=0.7, 95% CI 0.38 to 1.32, p=0.28). At LC diagnosis, the non-transplanted group was older than the transplanted group with average age of 67.7 versus 60.8 years, respectively (p=0.006). Both groups showed male predominance. In both groups, LC was primarily peripheral, lower lobe predominant and most frequently squamous cell carcinoma. The median survival time after LC diagnosis was 4 months in the transplanted group and 11 months in the non-transplanted group (p=0.19). Multivariate analysis showed improved survival in the non-transplanted group among those patients who received oncological treatment. Conclusion Chest CT should be performed regularly in order to evaluate IPF patients for potential LC. Single lung transplant IPF patients face an increased risk of post-transplant LC in the native fibrotic lung. Where practicable, IPF patients should be prioritised for double lung transplant.
1

26 April 2022 in Thoracic Cancer
Verified
Journal Article
Open access
EGEvgeni Gershman
Evgeni Gershman
IVIlya Vaynshteyn
Ilya Vaynshteyn
LFLev Freidkin
Lev Freidkin
BPBarak Pertzov
Barak Pertzov
DRDror Rosengarten
Dror Rosengarten
MKMordechai Reuven Reuven Kramer
Mordechai Reuven Reuven Kramer
Background: Adequate tissue sampling is fundamental for establishing a definitive diagnosis, assessing prognosis and tailoring therapy. Each of the methods for obtaining tissue (e.g., endoscopic, image guidance and surgical biopsies) results in a different diagnostic yield and complication rate profile.Objectives: Present feasibility, and assess safety and efficacy of freehand transthoracic ultrasound‐guided core‐needle biopsies (USGNB) of thoracic lesions performed by pulmonologist.Methods: A retrospective analysis study of ultrasound‐guided core‐needle biopsies of thoracic lesions performed at the Pulmonary Institute of Rabin Medical Center was conducted from September 2020 to October 2021. All core‐needle biopsies were performed under local anesthesia with guidance of Mindray TE7 2019 US system. Procedural variables including complications and pathological diagnostic yield were the primary end point. IRB 0671‐21‐RMC.Results: In total 91 biopsy procedures were analyzed in38 females and 53 males, average age 71.1 years. Twenty‐three (25.3%) cases were lung lesions, 7 (7.7%) – mediastinal, 13 (14.3%) – chest wall, 27 (29.7%) – pleural, and 21 (23.1%) supraclavicular lesions. Average lesion size was 51.6 mm, the largest in the mediastinum and the smallest in supraclavicular locations (97.7mm and 28.0 mm, respectively). Overall pathological diagnostic yield was 90%, highest success in chest wall (100%) and lowest in mediastinal biopsies (71.4%). We had only one complication –hemothorax resolved by chest tube drainage‐ accounting for only 1.1% complication rate.Conclusion: Safety and efficacy were demonstrated in freehand US‐guided core‐needle biopsy of thoracic lesions performed by pulmonologists. We suggest thoracic ultrasound and USG‐CNB be part of training and clinical practice in interventional pulmonology.

1 August 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
AMAndrea Mytinger
Andrea Mytinger
TTTrevor Taylor
Trevor Taylor
EGEvgeni Gershman
Evgeni Gershman
SSSamira Shojaee
Samira Shojaee